Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seeking Funds For Phase III Antibiotic, Paratek Files For IPO

This article was originally published in The Pink Sheet Daily

Executive Summary

The Boston-based drug developer believes it has resolved the regulatory issues that led to the dissolution of a partnership with Novartis around the drug omadacycline.

You may also be interested in...



Deal Watch: Genentech Pays Big For Seragon’s Early Assets

Genentech pays $725 million upfront for San Diego oncology firm Seragon, and Bluebird adds gene-editing and cell-signaling capabilities by acquiring Precision Genomic Engineering. It was a deal-heavy week ahead of the July 4th Holiday.

More And Better Biotech IPOs, But Step-Ups Still Lag

Higher valuations, better quality companies, improved aftermarket performance and a broadening investor pool are all conspiring to advance the state of biotech IPOs. But VCs continue to see little step-up at IPO.

Will New Antibiotic Incentives GAIN Investors’ Backing?

The GAIN Act is intended to spur development of new antibiotics, but incentives like extended market exclusivity and priority review, while important benefits, may not be enough to get investors off the sidelines.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel